Participated · Debt Financing · Aug 2026

DataVita operates and develops data center campus assets in the UK, including DV1 (operated since 2016) and a smaller DV2 site in Glasgow offering 130 racks across 1,000 sqm. The company acquired DV1 in 2021 with £45m of owner support and was built originally by HFD Group in 2021. It is expanding DV1 and building a new DV3 facility in the North Lanarkshire AI Growth Zone, with all capacity from both buildings contracted to CoreWeave under a 15-year lease. Last year CoreWeave announced deployments of Nvidia GPUs into DataVita data centers, and management states the first facility from the current program is due to complete this year. The company has secured project-level debt financing and a National Wealth Fund-backed guarantee to underwrite the current build-out.

Participated · Series B · Aug 2026

Mironid develops first-in-class small-molecule LoAc® drug candidates that directly target abnormally high kidney cAMP levels that drive cyst formation in ADPKD. Its lead programmes are focused on treating Autosomal Dominant Polycystic Kidney Disease, a hereditary disorder affecting over 12 million people worldwide with about 50% of patients developing kidney failure by age 60. The company was founded through collaboration between the University of Strathclyde and Heriot-Watt University and is led by CEO Neil Wilkie. Mironid has progressed a series of drug-development programmes targeting specific enzymes to generate differentiated therapies for diseases with high unmet need. The recently closed £34m Series B, which includes an £8.4m equity investment from SNIB and participation from Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde, will fund clinical development and advancement of its lead candidate.

Led · Equity · May 2026

EnteroBiotix is a clinical-stage biopharmaceutical company focused on full-spectrum microbiome therapeutics. Its lead product, EBX-102-02, is a next-generation full-spectrum microbiome therapeutic manufactured with proprietary processing technologies intended to enable safe, stable, orally delivered microbial ecosystem restoration. The company positions EBX-102-02 as a potential first disease-modifying therapy for IBS-C and advanced the candidate into a Phase 2b program following positive Phase 2a TrIuMPH trial results in 122 patients. The RISE Phase 2b trial is randomized, double-blind, placebo-controlled and plans to enroll around 300 patients in the UK, with first dosing expected in Q2 2026 and topline data due in H2 2027. EnteroBiotix is building a broader pipeline in high-value gastrointestinal indications associated with significant unmet need. EBX-102-02 is not approved for clinical therapeutic use outside of clinical trials or regulated programmes.

Led · Series A · Mar 2026

Bioliberty develops Lifehub, an AI- and robotics-enabled platform that monitors functional recovery and enhances physical and occupational therapy delivery in post-acute settings. The company launched Lifehub Clinic in 2025 and is commercializing Lifehub in the U.S. while preparing Lifehub Home to extend therapy and monitoring into patients’ homes. Bioliberty reports growing adoption among major U.S. rehabilitation providers, including partnerships with one of the largest rehabilitation networks and Sheltering Arms Institute, and collaborates with research organizations such as Mount Sinai and the U.S. Department of Veterans Affairs. It holds multiple patents across its core technologies and states that Lifehub and Lifeglov are FDA-registered. Founded in 2023, the company has raised $17.5 million to date and is using recent proceeds to expand computer vision, care coordination features, and U.S. commercialization efforts.

Led · Equity · Feb 2026

Headquartered in Inverness, Aurora Energy Services delivers inspection, maintenance, training, and technology products to renewable energy operators, helping maximise the lifespan and efficiency of wind and other clean-energy assets. The firm employs more than 100 people in Scotland and has expanded operations to the United States, Australia and Chile, complemented by six strategic acquisitions that broaden its service offering. Aurora is also developing proprietary technologies such as SQUID™ and Altitude to improve the economics of onshore and offshore wind projects. Management plans to use new capital to expand its Inverness training facility and add workshops and offices in Wick, Aberdeen and the U.S. The business forecasts revenue growth of roughly 30% this year, moving from £90 million in 2026 to about £120 million. By reskilling former oil-and-gas workers, the company positions itself as a key enabler of the global energy transition.